FDA To Probably Decide On Pfizer/BioNTech COVID-19 Booster Shots By Tomorrow: Bloomberg

Citing people familiar with the matter, Bloomberg reports that the FDA is expected to decide on Wednesday whether to recommend Pfizer Inc PFE and BioNTech SE BNTX COVID-19 vaccine as a booster shot.
Last Friday, an FDA advisory panel recommended against the broader use of the vaccine as an additional shot.
But the panel did endorse the booster shot in people aged 65 years and older and those at occupational exposure to COVID-19.
Related Link: FDA Panel Votes Against Approval Of Pfizer/BioNTech's COVID-19 Booster Shot For General Public.
Tomorrow, the regulators broaden the group of people who will be eligible for booster shots.
Earlier this month, the federal health officials reportedly asked the White House to push back the start of a planned COVID-19 booster campaign, at least for Moderna Inc MRNA and Johnson & Johnson JNJ.
Read Next: COVID-19 Vaccine Booster Shots Will Have To Wait, FDA Tells White House.
Yesterday, Pfizer and BioNTech reported encouraging data for its COVID-19 vaccine in one cohort of kids aged 5-11 years.
Price Action: Pfizer/BioNTech COVID-19 Vaccine Data For Kids Is Here: What You Need To Know.
Price Action: PFE stock is down 0.54% at $43.96, while BNTX stock is up 0.67% at $341.29 during the market session on the last check Tuesday.
Photo by x3 from Pixabay